Bicycle Therapeutics (BCYC) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $259.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | VOGX |
|---|---|---|
| Share price | $3.81 | $17.49 |
| Market cap | $266.67M | $259.82M |
| 1-day change | +2.14% | +8.23% |
| YTD return | -46.19% | — |
| 1-year return | -53.87% | — |
| 5-year return | -93.57% | — |
| EPS (TTM) | $-2.73 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $38.41 |
| 52-week low | $3.33 | $12.95 |
| Distance from 52-week high | -58.13% | -54.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +149.34% | +214.47% |
| Average volume | 387.29K | 187.66K |
| Shares outstanding | 50.55M | 14.86M |
| Employees | 288 | 4 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Bicycle Therapeutics in Healthcare and Vogenx in Health Care.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Healthcare · Biotechnology · 288 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
BCYC vs VOGX FAQ
Which is bigger, Bicycle Therapeutics or Vogenx?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $259.82M for Vogenx (VOGX).
Are Bicycle Therapeutics and Vogenx in the same industry?
No. Bicycle Therapeutics is in the Healthcare sector, while Vogenx is in Health Care.